Literature DB >> 8535658

Cost-effectiveness analysis: are the outputs worth the inputs?

D Naylor.   

Abstract

Mesh:

Year:  1996        PMID: 8535658

Source DB:  PubMed          Journal:  ACP J Club        ISSN: 1056-8751


× No keyword cloud information.
  6 in total

1.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

2.  NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial.

Authors:  M G Franzosi; A P Maggioni; E Santoro; G Tognoni; E Cavalieri
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

5.  Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

Authors:  M G Franzosi; M Brunetti; R Marchioli; R M Marfisi; G Tognoni; F Valagussa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Population-based utilities for upper extremity functions in the setting of tetraplegia.

Authors:  Ashwin N Ram; Catherine M Curtin; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2009-11       Impact factor: 2.230

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.